Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine SR in Overactive Bladder Syndrome
NCT00138723Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2003
- Primary completion
- Feb 2005
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of fesoterodine in overactive bladder syndrome (OAB), sponsored by Pfizer. Started Oct 2003; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT00138723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00138723.